Current perspectives in HIV post-exposure prophylaxis

References

• Joint United NationsProgramme on HIV/AIDS (UNAIDS)Global report: UNAIDS report on the global AIDS epidemic 2013Geneva, SwitzerlandUNAIDS2013 Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdfAccessed December 26, 2013
   Google Scholar
• PintoLALandayALBerzofskyJAKesslerHAShearerGMImmune response to human immunodeficiency virus (HIV) in health care workers occupationally exposed to HIV-contaminated bloodAm J Med19971025B21249845492
   PubMedGoogle Scholar
• SpiraAIMarxPAPattersonBKCellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaquesJ Exp Med199618312152258551225
   PubMed Web of Science ®Google Scholar
• ValcourVChalermchaiTSailasutaNRV254/SEARCH 010 Study GroupCentral nervous system viral invasion and inflammation during acute HIV infectionJ Infect Dis2012206227528222551810
   PubMed Web of Science ®Google Scholar
• MillerRJCairnsJSBridgesSSarverNHuman immunodeficiency virus and AIDS: insights from animal lentivirusesJ Virol200074167187719510906172
   PubMed Web of Science ®Google Scholar
• BourryOManniouiASellierPEffect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusionRetrovirology201077820868521
   PubMed Web of Science ®Google Scholar
• García-LermaJGCongMEMitchellJIntermittent prophylaxis with oral truvada protects macaques from rectal SHIV infectionSci Transl Med201021414ra4
   PubMed Web of Science ®Google Scholar
• TsaiCCEmauPFollisKEEffectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatmentJ Virol1998725426542739557716
   PubMed Web of Science ®Google Scholar
• OttenRASmithDKAdamsDREfficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2)J Virol200074209771977511000253
   PubMed Web of Science ®Google Scholar
• Le GrandRVaslinBLargheroLPost-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimeraAIDS2000141218461866
   Web of Science ®Google Scholar
• SperlingRSShapiroDECoombsRWMaternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study GroupN Engl J Med199633522162116298965861
   PubMed Web of Science ®Google Scholar
• WadeNABirkheadGCWarrenBLAbbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virusN Engl J Med199833920140914149811915
   PubMed Web of Science ®Google Scholar
• Nielsen-SainesKWattsDHVelosoVGNICHD HPTN 040/PACTG 1043 Protocol TeamThree postpartum antiretroviral regimens to prevent intrapartum HIV infectionN Engl J Med2012366252368237922716975
   PubMed Web of Science ®Google Scholar
• CardoDMCulverDHCiesielskiCAA case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance GroupN Engl J Med199733721148514909366579
   PubMed Web of Science ®Google Scholar
• TomkinsSNcubeFOccupationally acquired HIV: international reports to Dec 2002Euro Surveill2005103E050310.216702637
   PubMedGoogle Scholar
• SchechterMdo LagoRFMendelsohnABBehavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIVJ Acquir Immune Defic Syndr200435551952515021317
   PubMed Web of Science ®Google Scholar
• BryantJBaxterLHirdSNon-occupational postexposure prophylaxis for HIV: a systematic reviewHealth Technol Assess20091314iiiixx160
   Web of Science ®Google Scholar
• JinFJanssonJLawMPer-contact probability of HIV transmission in homosexual men in Sydney in the era of HAARTAIDS201024690791320139750
   PubMed Web of Science ®Google Scholar
• BaggaleyRFWhiteRGBoilyMCHIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV preventionInt J Epidemiol20103941048106320406794
   PubMed Web of Science ®Google Scholar
• MastroTDde VincenziIProbabilities of sexual HIV-1 transmissionAIDS199610Suppl AS75S828883613
   PubMedGoogle Scholar
• CohenMSYingCQMcCauleyMHPTN 052 Study TeamPrevention of HIV-1 infection with early antiretroviral therapyN Engl J Med2011365649350521767103
   PubMed Web of Science ®Google Scholar
• PowersKAPooleCPettiforAECohenMSRethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysisLancet Infect Dis20088955356318684670
   PubMed Web of Science ®Google Scholar
• VitinghoffEDouglasJJudsonFMcKirnanDMacQueenKBuchbinderSPPer-contact risk of human immunodeficiency virus transmission between male sexual partnersAm J Epid19991503306311
   PubMed Web of Science ®Google Scholar
• AghaizuABrownAENardoneAHIV in the United Kingdom 2013 Report: data to end 2012London, UKPublic Health England2013 Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317140300680Accessed January 3, 2014
   Google Scholar
• PowersKAGhaniACMillerWCThe role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling studyLancet2011378978725626821684591
   PubMed Web of Science ®Google Scholar
• MillerWCRosenbergNERutsteinSEPowersKARole of acute and early HIV infection in the sexual transmission of HIVCurr Opin HIV AIDS20105427728220543601
   PubMed Web of Science ®Google Scholar
• Writing GroupWilliamsIChurchillDBritish HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated Nov 2013. All changed text is cast in yellow highlight.). HIV MedJan201415Suppl 1185
   Google Scholar
• RodgerABruunTCambianoVHIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER StudyPresented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI) 2014March 3–6, 2014Boston, MA Abstract #153LB
   Google Scholar
• RøttingenJACameronDWGarnettGPA systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?Sex Transm Dis2001281057959711689757
   PubMed Web of Science ®Google Scholar
• HayesRMoshaFNicollAA community trial of the impact of improved sexually transmitted disease treatment on the HIV epidemic in rural Tanzania: 1. DesignAIDS199598916926
   Web of Science ®Google Scholar
• GrosskurthHMoshaFToddJImpact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trialLancet199534689745305367658778
   PubMed Web of Science ®Google Scholar
• CohenMSHoffmannIFRoyceRAReduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research GroupLancet19973499069186818739217758
   PubMed Web of Science ®Google Scholar
• RothenbergRBScarlettMdel RioCReznikDO’DanielsCOral transmission of HIVAIDS19981216209521059833850
   PubMed Web of Science ®Google Scholar
• AuvertBTaljaardDLagardeERandomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 TrialPLoS Med2005211e29816231970
   PubMed Web of Science ®Google Scholar
• BaileyRCMosesSParkerCBMale circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trialLancet2007369956264365617321310
   PubMed Web of Science ®Google Scholar
• GrayRHKigoziGSerwaddaDMale circumcision for HIV prevention in men in Rakai, Uganda: a randomised trialLancet2007369956265766617321311
   PubMed Web of Science ®Google Scholar
• MillettGAFloresSAMarksGReedJBHerbstJHCircumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysisJAMA2008300141674168418840841
   PubMed Web of Science ®Google Scholar
  Erratum inJAMA2009301111126112919293412
   PubMed Web of Science ®Google Scholar
• WiysongeCSKongnyuyEJSheyMMale circumcision for prevention of homosexual acquisition of HIV in menCochrane Database Syst Rev20116CD00749621678366
   PubMed Web of Science ®Google Scholar
• New York State Department of Health AIDS InstituteHIV Prophylaxis Following Non-Occupational ExposureNew York, NYHIV Clinical Resource2008 Available at: http://www.hivguidelines.org/clinical-guidelines/post-exposure-prophylaxis/hiv-prophylaxis-following-non-occupational-exposure-including-sexual-assault/Accessed July 12, 2012
   Google Scholar
• OttenRASmithDKAdamsDREfficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2)J Virol200074209771977511000253
   PubMed Web of Science ®Google Scholar
• UK Department of HealthHIV post-exposure prophylaxis: guidance from the UK Chief Medical Officers’ Expert Advisory Group on AIDSLondon, UKDepartment of Health2008 Available at: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_088185?ssSourceSiteId=abAccessed on February 1, 2014
   Google Scholar
• RoedlingSReevesICopasAJChanges in the provision of post-exposure prophylaxis for HIV after sexual exposure following introduction of guidelines and publicity campaignsInt J STD AIDS200819424124218482942
   PubMed Web of Science ®Google Scholar
• DaySMearsABondKKulasegaramRPost-exposure HIV prophylaxis following sexual exposure: a retrospective audit against recent draft BASHH guidanceSex Transm Infect200682323623716731676
   PubMed Web of Science ®Google Scholar
• ParkinJMMurphyMAndersonJEl-GadiSForsterGPinchingAJTolerability and side-effects of post-exposure prophylaxis for HIV infectionLancet2000355920572273310703807
   PubMed Web of Science ®Google Scholar
• KahnJOMartinJNRolandMEFeasibility of post-exposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injecting drug use exposure: the San Fransisco PEP StudyJ Infect Dis2001183570771411181146
   PubMed Web of Science ®Google Scholar
• RolandMENeilandsTBKroneMRSeroconversion following nonoccupational postexposure prophylaxis against HIVClin Infect Dis200541101507151316231265
   PubMed Web of Science ®Google Scholar
• OldenburgCEBärnighausenTHarlingGMimiagaMJMayerKHAdherence to post-exposure prophylaxis for non-forcible sexual exposure to HIV: a systematic review and meta-analysisAIDS Behav201418221722523877791
   PubMed Web of Science ®Google Scholar
• ChackoLFordNSbaitiMSiddiquiRAdherence to HIV post-exposure prophylaxis in victims of sexual assault: a systematic review and meta-analysisSex Transm Infect201288533534122332148
   PubMed Web of Science ®Google Scholar
• JochimsenEMLuoCCBeltramiJFRespessRASchableCACardoDMInvestigations of possible failures of postexposure prophylaxis following occupational exposures to human immunodeficiency virusArch Intern Med1999159192361236310547177
   PubMedGoogle Scholar
• UK Collaborative Group on HIV Drug ResistanceUK Collaborative HIV Cohort StudyUK Register of HIV SeroconvertersEvidence of a decline in transmitted HIV-1 drug resistance in the United KingdomAIDS20072181035103917457098
   PubMed Web of Science ®Google Scholar
• VercauterenJWensingAMvan de VijverDATransmission of drug-resistant HIV-1 is stabilizing in EuropeJ Infect Dis2009200101503150819835478
   PubMed Web of Science ®Google Scholar
• GuptaRKJordanMRSultanBJGlobal trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysisLancet201238098491250125822828485
   PubMed Web of Science ®Google Scholar
• PolesMAElliottJVingerhoetsJDespite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasmaJ Infect Dis2001183114314811087199
   PubMed Web of Science ®Google Scholar
• ElseLJTaylorSBackDJKhooSHPharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tractAntivir Ther20111681149116722155899
   PubMed Web of Science ®Google Scholar
• BennPDMerceyDEBrinkNScottGWilliamsIGProphylaxis with a nevirapine-containing triple regimen after exposure to HIV-1Lancet2001357925768768811247556
   PubMed Web of Science ®Google Scholar
• LiuAYGrantRMBuchbinderSPPreexposure prophylaxis for HIV: unproven promise and potential pitfallsJAMA2006296786386516905792
   PubMed Web of Science ®Google Scholar
• KalichmanSPost-exposure prophylaxis for HIV infection in gay and bisexual men. Implications for the future of HIV preventionAm J Prevent Med1998152120127
   PubMed Web of Science ®Google Scholar
• DonnellDMimiagaMJMayerKChesneyMKoblinBCoatesTUse of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trialAIDS Behav20101451182118920490908
   PubMed Web of Science ®Google Scholar
• MartinJNRolandMENeilandsTBUse of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behaviorAIDS200418578779215075514
   PubMed Web of Science ®Google Scholar
• GrantRMLamaJRAndersonPLiPrEx Study TeamPreexposure chemoprophylaxis for HIV prevention in men who have sex with menN Engl J Med2010363272587259921091279
   PubMed Web of Science ®Google Scholar
• MoyleGJDeJesusECahnPZiagen Once-Daily in Antiretroviral Combination Therapy (CNA30021) Study TeamAbacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination StudyJ Acquir Immune Defic Syndr200538441742515764958
   PubMed Web of Science ®Google Scholar
• EasterbrookPJWatersAMuradSEpidemiological risk factors for hypersensitivity reactions to abacavirHIV Med20034432132414525543
   PubMedGoogle Scholar
• BaetanJDonnellDNdasePARV PrEP for HIV-1 prevention among heterosexual men and women19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)March 5–8, 2012Seattle, WA abstr 29
   Google Scholar
• ThigpenMCKebaabetswePMPaxtonLATDF2 Study GroupAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in BotswanaN Engl J Med2012367542343422784038
   PubMed Web of Science ®Google Scholar
• HendrixCMinnisAGudderaVMTN-001: a Phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations18th Conference on Retroviruses and Opportunistic InfectionsFebruary 27–March 2, 2011Boston, MA abstr 35LB
   Google Scholar
• KarimSSKashubaADWernerLKarimQADrug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in womenLancet2011378978727928121763939
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures – worldwide, 1997–2000MMWR Morb Mortal Wkly Rep20014951–521153115611198946
   PubMedGoogle Scholar
• Intelence Summary of Product Characteristics [webpage on the Internet]High Wycombe, UKJanssen-Cilag International NV2012 Available at: http://www.medicines.org.uk/emc/medicine/21185/SPC/Accessed July 12, 2013
   Google Scholar
• Andrew CarrSafety, Tolerability, and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men. (EPEP) Available from: http://clinicaltrials.gov/ct2/show/NCT01715636. NLM identifier: NCT01715636Accessed February 1, 2014
   Google Scholar
• Janssen-Cilag GmbHHuman Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar) Available from: http://clinicaltrials.gov/ct2/show/NCT01516970. NLM identifier: NCT01516970Accessed February 1, 2014
   Google Scholar
• BennPFisherMKulasegaramRBASHHPEPSE Guidelines Writing Group Clinical Effectiveness GroupUK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011)Int J STD AIDS2011221269570822174049
   PubMed Web of Science ®Google Scholar
• EronJJrYeniPGatheJJrKLEAN study teamThe KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialLancet2006368953447648216890834
   PubMed Web of Science ®Google Scholar
• Diaz-BritoVLeónAKnobelHDATEMPEP study groupPost-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudineAntivir Ther201217233734622293542
   PubMed Web of Science ®Google Scholar
• WinstonAMcAllisterJAminJCooperDACarrAThe use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxisHIV Med20056319119715876286
   PubMed Web of Science ®Google Scholar
• McAllisterJReadPMcNultyATongWWIngersollACarrARaltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherenceHIV Med2014151132224007390
   PubMed Web of Science ®Google Scholar
• RockstrohJKLennoxJLDejesusESTARTMRK InvestigatorsLong-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKClin Infect Dis201153880781621921224
   PubMed Web of Science ®Google Scholar
• MayerKHMimiagaMJGelmanMGrassoCRaltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherenceJ Acquir Immune Defic Syndr201259435435922267017
   PubMed Web of Science ®Google Scholar
• New York State Department of Health AIDS InstituteHIV prophylaxis following occupational exposureNew York, NYHIV Clinical Resource2012 Available at: http://www.hivguidelines.org/clinical-guidelines/post-exposure-prophylaxis/hiv-prophylaxis-following-occupational-exposure/Accessed December 26, 2013
   Google Scholar
• KennethHMayerMDGilead SciencesHIV Non-Occupational Post-Exposure Prophylaxis (QUAD) Available from: http://clinicaltrials.gov/ct2/show/NCT01855867. NLM identifier: NCT01855867Accessed February 1, 2014
   Google Scholar
• CooperDAHeeraJGoodrichJMaraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infectionJ Infect Dis2010201680381320151839
   PubMed Web of Science ®Google Scholar
• Hospital Clinic of BarcelonaStudy Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: FOVIR + EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR + EMTRICITABINA + MARAVIROC (MARAVI-PEP) Available from: http://clinicaltrials.gov/ct2/show/NCT01533272. NLM identifier: NCT01533272Accessed July 12, 2012
   Google Scholar
• Tolerability and completion of Maraviroc compared to Kaletra^® in combination with Truvada^® for HIV Post Exposure Prophylaxis Ref. ISRCTN63350011. Available from: http://www.controlled-trials.com/ISRCTN63350011/Accessed July 12, 2012
   Google Scholar
• Evaluating the safety and tolerability of antiretroviral drug regimens used as pre-exposure prophylaxis to prevent HIV infection in men who have sex with men Available from: at http://clinicaltrials.gov/ct2/show/NCT01505114. NLM identifier: NCT01505114Accessed July 12, 2012
   Google Scholar
• BrownKCPattersonKBMaloneSASingle and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative menJ Infect Dis2011203101484149021502084
   PubMed Web of Science ®Google Scholar
• DumondJBPattersonKBPechaALMaraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative womenJ Acquir Immune Defic Syndr200951554655319546811
   PubMed Web of Science ®Google Scholar
• ClavelCPeytavinGTubianaRRaltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)Antimicrob Agents Chemother20115563018302121444705
   PubMed Web of Science ®Google Scholar
• CalcagnoABonoraSD’AvolioARaltegravir penetration in seminal plasma of healthy volunteersAntimicrob Agents Chemother20105462744274520308369
   PubMed Web of Science ®Google Scholar
• KoberCNixonEFisherMRoutine monitoring of bloods for toxicity when using modern post-exposure prophylaxis (PEP) regimens may be unnecessarySecond BHIVA/BASHH Joint ConferenceApril 20–23, 2010Manchester, UK abstr P98
   Google Scholar
• WilliamsIChurchillDAndersonJBritish HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012HIV Medicine201415Suppl 1185
   Google Scholar
• Truvada film-coated tablets [webpage on the internet]Gilead Sciences Ltd2014 Available from: http://www.medicines.org.uk/emc/medicine/15826/SPC/Truvada+film-coated+tablets/Accessed July 17, 2014
   Google Scholar
• Viread 245 mg film-coated tablets [webpage on the internet]Gilead Sciences Ltd2014 Available from: http://www.medicines.org.uk/emc/medicine/9008/SPC/Viread+245+mg+film-coated+tablets/Accessed July 17, 2014
   Google Scholar
• SmithDKGrohskopfLABlackRJUS Department of Health and Human ServicesAntiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human ServicesMMWR Recomm Rep200554RR-212015660015
   PubMedGoogle Scholar
• SnellLEdwardsSGBennPDPotential impact of updated UK guidelines for use of post exposure prophylaxis following sexual exposure in a London sexual health serviceBASHH-ASTDA 4th Joint MeetingJune 27–29, 2012Brighton, UK abstr P20
   Google Scholar
• European AIDS Clinical Society (EACS)Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe (v7)Brussels, BelgiumEuropean AIDS Clinical Society2013 Available from: http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdfAccessed January 2, 2014
   Google Scholar
• Australian Society of HIV Medicine (ASHM)Post-Exposure Prophylaxis after Non-Occupational and Occupational Exposure to HIV: National GuidelinesSurry Hills, AustraliaAustralian Society of HIV Medicine2013 Available from: http://www.ashm.org.au/pep-guidelines/NPEPPEPGuidelinesDec2013.pdfAccessed January 1, 2014
   Google Scholar
• JoshiMBasraAMcCormickCWebbHPakianathanMPost-exposure prophylaxis after sexual exposure (PEPSE) awareness in an HIV-positive cohortInt J STD AIDS2014251676923970629
   PubMed Web of Science ®Google Scholar
• RodríguezAECastelADParishCLHIV medical providers’ perceptions of the use of antiretroviral therapy as nonoccupational postexposure prophylaxis in 2 major metropolitan areasJ Acquir Immune Defic Syndr201364Suppl 1S68S7924126450
   PubMed Web of Science ®Google Scholar
• HankinsCAde ZalduondoBOCombination prevention: a deeper understanding of effective HIV preventionAIDS201024Suppl 4S70S8021042055
   PubMed Web of Science ®Google Scholar
• PaxtonLAHopeTJaffeHWPre-exposure prophylaxis for HIV infection: what if it works?Lancet20073709581899317617276
   PubMed Web of Science ®Google Scholar
• Joint United NationsProgramme on HIV/AIDS (UNAIDS). Global reportGeneva, SwitzerlandUNAIDS2010 Available at: http://www.unaids.org/globalreport/Global_report.htmAccessed February 1, 2014
   Google Scholar